Oculus (OCLS) Issues Several Key Updates; Reports Trailing 12-Month Revs of $12.1M

In compliance with SEC Regulation FD requirements or "fair disclosure" of material information, Hoji Alimi, founder and CEO of Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today outlined key business updates discussed during an interview with BioMedReports at the Roth Capital Growth Conference on March 14. The video interview is anticipated to be made available online in the near future. The following updates were provided:

• Oculus has reduced its burn from $18 million annually in fiscal year ended March 31, 2008 to just $3 million for the first nine months of the current fiscal year.
  
  
• Company was within $35,000 EBITDAS breakeven in quarter ending September 2011.
  
  
• Trailing revenue for the 12 months ended December 31, 2011 of $12.1 million.
  
  
• Three Oculus partners (Eloquest, Onset, Quinnova) are currently launching multiple new Microcyn-based products into U.S. dermatology and hospital wound-care markets.
  
  
• Company intends to finalize development of a Microcyn-based formulation for the surgical market, with plans to enter into discussion with the FDA for design of regulatory process.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Elroy Air wins $46M U.S. Army contract for cargo drone system
• ESS Tech closes $3.2M stock offering at $0.50 per share
• Rosenblatt Reiterates Buy Rating on Super Micro Computer (SMCI)